Family Care

Why is Family Care Hospitals Ltd falling/rising?

As of 01-Sep, Family Care Hospitals Ltd's stock price is falling at 1.99, down -3.4%. The stock has significantly underperformed, with a year-to-date decline of -47.49% and a -54.15% drop over the past year, indicating a persistent bearish trend and decreased investor interest.

As of 01-Sep, Family Care Hospitals Ltd's stock price is falling, currently at 1.99, which reflects a change of -0.07 or -3.4%. The stock has been underperforming significantly, with a decline of -2.93% over the past week and a staggering -30.90% over the past month. Year-to-date, the stock has decreased by -47.49%, and over the past year, it has fallen by -54.15%. <BR><BR>The stock has been on a downward trend, having lost value for the last two consecutive days, resulting in a total decline of -4.78% during this period. Additionally, Family Care Hospitals Ltd is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent bearish trend. <BR><BR>Investor participation has also decreased, with delivery volume dropping by -65.15% compared to the 5-day average, suggesting a lack of interest from investors. Overall, these factors contribute to the stock's falling price, reflecting broader challenges faced by the company in the market.

Who are in the management team of Family Care?

The management team of Family Care includes Rajnish Kumar Pandey (Independent Director), Pandoo Neig (Managing Director), Dhananjay Parikh (Non-Executive & Independent Director), and Lucy Massey (Additional Non-Executive Director).

The management team of Family Care includes the following individuals:<BR><BR>1. Rajnish Kumar Pandey - Independent Director<BR>2. Pandoo Neig - Managing Director<BR>3. Dhananjay Parikh - Non-Executive & Independent Director<BR>4. Lucy Massey - Additional Non-Executive Director<BR><BR>If you need more details about their roles or the company's operations, feel free to ask!

What does Family Care do?

Family Care Hospitals Ltd operates in the healthcare services sector as a micro-cap company, with recent quarterly net sales and profit reported at 0 Cr. Established in 1982, it has undergone several name changes and currently has a market cap of INR 11 Cr.

Overview:<BR>Family Care Hospitals Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was initially established as a partnership firm in 1982 and became a public limited company in September 1994 under the name Pharma Offset Limited. It underwent several name changes, becoming Pharma Com (India) Limited in June 2000 and Count N Denier (India) Limited in March 2012. The most recent quarterly results reported net sales and net profit of 0 Cr for June 2026.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 0 Cr (Quarterly Results - Jun 2026)<BR>- Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>- Market-cap value: INR 11 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 67<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.59<BR>- Return on Equity: -50.67%<BR>- Price to Book: 1.39<BR><BR>Contact Details:<BR>- Address: Plot No A-357 Road No 26, Wagle Industrial Estate MIDC Thane (West) Maharashtra : 400604<BR>- Phone: 91-22-25833205<BR>- Email: csscandent@gmail.com<BR>- Website: http://www.scandent.in

Who are the peers of the Family Care?

Family Care's peers include Samsrita Labs, Adeshwar Meditex, Transgene Biotek, Vanta Bioscience, Dhanvantri Jeev., Looks Health, Clinitech Lab, Ashram Online, and Dr Lalchand. Lab. Family Care has average management risk, excellent capital structure, and a 1-year return of -52.09%, while Dhanvantri Jeev. shows the highest return at 26.19%.

Peers: The peers of Family Care are Samsrita Labs, Adeshwar Meditex, Transgene Biotek, Vanta Bioscience, Dhanvantri Jeev., Looks Health, Clinitech Lab, Ashram Online, and Dr Lalchand. Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dhanvantri Jeev., while Average management risk is found at Family Care. Below Average management risk is noted at Adeshwar Meditex, Vanta Bioscience, Clinitech Lab, and Dr Lalchand. Lab, and the rest do not qualify. Good growth is seen at Family Care and Dhanvantri Jeev., while Below Average growth is present at Adeshwar Meditex, Vanta Bioscience, and Clinitech Lab, and the rest do not qualify. Family Care has an Excellent capital structure, while Good capital structure is observed at Dhanvantri Jeev. and Clinitech Lab, and Average capital structure is noted at Adeshwar Meditex, with the rest not qualifying.<BR><BR>Return Snapshot: Dhanvantri Jeev. has the highest 1-year return at 26.19%, while Family Care has the lowest at -52.09%. Family Care's 1-year return is significantly lower than that of Dhanvantri Jeev. Additionally, Clinitech Lab and Dr Lalchand. Lab have negative six-month returns.

How big is Family Care?

As of 31st August, Family Care Hospitals Ltd has a market capitalization of 11.00 Cr and reported Net Sales of 0.24 Cr with a Net Profit loss of 8.41 Cr over the latest four quarters. Shareholder's Funds were valued at 13.46 Cr, and Total Assets amounted to 46.09 Cr as of March 2025.

As of 31st August, Family Care Hospitals Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Family Care reported Net Sales of 0.24 Cr. However, the company experienced a loss of 8.41 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. At that time, Shareholder's Funds were valued at 13.46 Cr, while Total Assets amounted to 46.09 Cr.

Which are the latest news on Family Care?

When is the next results date for Family Care Hospitals Ltd?

The next results date for Family Care Hospitals Ltd is 24 July 2026.

The next results date for Family Care Hospitals Ltd is scheduled for 24 July 2026.

Is Family Care overvalued or undervalued?

As of October 29, 2025, Family Care is considered overvalued and risky due to severe profitability issues, reflected in a negative PE ratio of -3.62 and a year-to-date return of -35.44%, significantly underperforming compared to its peers like Max Healthcare and Apollo Hospitals.

As of 29 October 2025, Family Care's valuation grade has moved from fair to risky, indicating a significant deterioration in its financial standing. The company is currently deemed overvalued, with a PE ratio of -3.62, an EV to EBITDA of -3.48, and a ROE of -47.73%. These figures suggest severe profitability issues, particularly when compared to its peers. For instance, Max Healthcare has a PE ratio of 96.03 and an EV to EBITDA of 59.47, while Apollo Hospitals shows a PE of 71.83 and an EV to EBITDA of 36.92, both indicating a stark contrast in financial health.<BR><BR>The company’s performance has been notably poor, with a year-to-date return of -35.44%, significantly underperforming the Sensex, which has returned 8.78% in the same period. Given the substantial negative ratios and the company's poor performance relative to its peers, Family Care is clearly overvalued in the current market context.

Are Family Care latest results good or bad?

Family Care Hospitals' latest results are concerning, showing a net loss of ₹4.61 crores in Q2 FY26, a 558.57% decline from the previous quarter, and revenue dropping 98.20% year-on-year to just ₹0.07 crores. These figures indicate severe operational challenges and raise significant concerns about the company's viability.

The latest results for Family Care Hospitals are quite concerning and indicate a severe operational crisis. In Q2 FY26, the company reported a net loss of ₹4.61 crores, which is a staggering 558.57% decline compared to the previous quarter. Revenue has plummeted to just ₹0.07 crores, reflecting a 98.20% year-on-year drop from ₹3.88 crores in Q2 FY25. This dramatic decline in revenue suggests that the company has virtually ceased meaningful operations.<BR><BR>The operating margin is alarmingly negative at -6,271.43%, indicating that the core business is generating massive losses. Furthermore, the profit after tax (PAT) margin is also deeply negative at -6,585.71%, which signifies that the company is losing more than ₹65 for every rupee of revenue.<BR><BR>Overall, these results paint a picture of a company in distress, facing significant challenges to its business model and sustainability. The financial metrics suggest a critical need for immediate intervention to address these issues, as the current trajectory raises serious questions about the company's viability moving forward.

How has been the historical performance of Family Care?

Family Care's historical performance has been volatile, with net sales peaking at 47.30 Cr in March 2023 but plummeting to 7.90 Cr by March 2025, alongside significant declines in operating income and total assets. Despite a rise in operating profit due to negative expenditures, profit before tax fell sharply to -44.47 Cr in March 2025.

Answer:<BR>The historical performance of Family Care has shown significant fluctuations over the years, particularly in net sales and profitability. <BR><BR>Breakdown:<BR>Family Care's net sales peaked at 47.30 Cr in March 2023 but dramatically fell to 7.90 Cr by March 2025. This decline in sales is reflected in the total operating income, which also decreased from 40.01 Cr in March 2024 to 7.90 Cr in March 2025. The company's total expenditure, which was 33.26 Cr in March 2024, turned negative at -20.51 Cr in March 2025, indicating a drastic change in operational efficiency. Operating profit, which had been positive in previous years, saw a significant rise to 31.56 Cr in March 2025, largely due to the negative expenditure. However, the profit before tax plummeted to -44.47 Cr in March 2025, following an exceptional item of -74.62 Cr. Consequently, profit after tax also fell to -44.15 Cr. The company's total assets decreased from 69.96 Cr in March 2024 to 46.09 Cr in March 2025, while total liabilities also dropped from 69.96 Cr to 46.09 Cr in the same period. Cash flow from operating activities turned negative at -17.00 Cr in March 2025, contrasting with the previous year's positive cash flow. Overall, Family Care's financial performance has been marked by volatility, particularly in sales and profitability metrics.

Should I buy, sell or hold Family Care?

What is the technical trend for Family Care?

As of May 30, 2025, Family Care's technical trend has shifted to a bearish stance with weak strength, supported by bearish daily moving averages and mixed signals from MACD and KST, while significantly underperforming against the Sensex.

As of 30 May 2025, the technical trend for Family Care has changed from mildly bearish to bearish. The current stance is bearish with weak strength, primarily driven by the daily moving averages indicating a bearish trend and both weekly and monthly Bollinger Bands confirming a bearish outlook. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly, indicating mixed signals. The KST is mildly bullish weekly but bearish monthly, further contributing to the overall bearish sentiment. The stock has underperformed significantly compared to the Sensex over multiple time frames, which reinforces the bearish outlook.

Who are the top shareholders of the Family Care?

The top shareholders of Family Care are primarily individual investors, holding 75.59% of the company. Gautam Mohan Deshpande is the largest promoter with 11.44%, while the highest public shareholder is Bala Venkata Reddy Ummalareddy at 1.02%, with no holdings from mutual funds or foreign institutional investors.

The top shareholders of Family Care primarily consist of individual investors, who hold a significant 75.59% of the company. The majority of the shareholding is non-institutional, with Gautam Mohan Deshpande being the promoter with the highest holding at 11.44%. The highest public shareholder is Bala Venkata Reddy Ummalareddy, who holds 1.02%. Additionally, there are no holdings reported from mutual funds or foreign institutional investors.

Has Family Care declared dividend?

No Dividend History Available